The productivity crisis in pharmaceutical R&D

Nature Reviews Drug Discovery

Mining the Wnt pathway for cancer therapeutics

Nick Barker, Hans C. Clevers 2006-12-01 · Read paper → Nature Reviews Drug Discovery

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics

Eric H. Karran, Bart De Strooper 2022-02-17 · Read paper → Nature Reviews Drug Discovery

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

Oleg V. Evgenov, Pál Pacher et al. 2006-09-01 · Read paper → Nature Reviews Drug Discovery

Therapeutically harnessing extracellular vesicles

Lesley Cheng, Andrew Francis Hill 2022-03-02 · Read paper → Nature Reviews Drug Discovery

Signalling bias in new drug discovery: detection, quantification and therapeutic impact

Terry Kenakin, Arthur Christopoulos 2012-02-15 · Read paper → Nature Reviews Drug Discovery

The drug–target residence time model: a 10-year retrospective

Robert A. Copeland 2015-12-18 · Read paper → Nature Reviews Drug Discovery

Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases

Robert A. Casero, Laurence J. Marton 2007-04-27 · Read paper → Nature Reviews Drug Discovery

Drugging p53 in cancer: one protein, many targets

Ori Hassin, Moshe Oren 2022-10-10 · Read paper → Nature Reviews Drug Discovery

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling

Joanne Bowes, Andrew J. Brown et al. 2012-11-30 · Read paper → Nature Reviews Drug Discovery

Antibody targeted drugs as cancer therapeutics

David Schrama, Ralph A. Reisfeld, Jürgen Christian Becker 2006-01-20 · Read paper → Nature Reviews Drug Discovery

Biased signalling: from simple switches to allosteric microprocessors

Jeffrey S. Smith, Robert J. Lefkowitz, Sudarshan Rajagopal 2018-01-05 · Read paper → Nature Reviews Drug Discovery

Targeting key proximal drivers of type 2 inflammation in disease

Namita A. Gandhi, Brandy Lee Bennett et al. 2015-10-16 · Read paper →